{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:22:58Z","timestamp":1792653778880,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2019.12.039","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T23:30:03Z","timestamp":1579390203000},"page":"4495-4506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Opportunities for an atherosclerosis vaccine: From mice to humans"],"prefix":"10.1016","volume":"38","author":[{"given":"Payel","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal J.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Kobiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanal","family":"Ghosheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.039_b0005","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","article-title":"Immune and inflammatory mechanisms of atherosclerosis (*)","volume":"27","author":"Galkina","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.vaccine.2019.12.039_b0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0025","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/01.ATV.21.6.1011","article-title":"Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice","volume":"21","author":"Reardon","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0030","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1073\/pnas.0409015102","article-title":"T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses","volume":"102","author":"Buono","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.12.039_b0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0021-9150(99)00011-8","article-title":"Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines","volume":"145","author":"Frostegard","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0045","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.106.633263","article-title":"Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule","volume":"114","author":"Gotsman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.ATV.0000259365.31469.89","article-title":"Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis","volume":"27","author":"Mor","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2174\/1389450117666161229142155","article-title":"The two faces of interleukin-17A in atherosclerosis","volume":"18","author":"Akhavanpoor","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.vaccine.2019.12.039_b0060","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41467-018-03493-5","article-title":"Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis","volume":"9","author":"Gaddis","year":"2018","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.vaccine.2019.12.039_b0065","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/CIRCULATIONAHA.118.034076","article-title":"LDL-reactive T cells regulate plasma cholesterol levels and development of atherosclerosis in humanized hypercholesterolemic mice","volume":"138","author":"Gistera","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0070","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/CIRCRESAHA.117.306044","article-title":"B-1b cells secrete atheroprotective IgM and attenuate atherosclerosis","volume":"117","author":"Rosenfeld","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCRESAHA.111.248542","article-title":"B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions","volume":"109","author":"Kyaw","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3389\/fimmu.2018.00911","article-title":"The contribution of autoantibodies to inflammatory cardiovascular pathology","volume":"9","author":"Meier","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0085","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/ATVBAHA.118.312272","article-title":"B cell fcgamma receptor IIb modulates atherosclerosis in male and female mice by controlling adaptive germinal center and innate B-1-cell responses","volume":"39","author":"Bagchi-Chakraborty","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0090","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/CIRCULATIONAHA.118.038534","article-title":"Germinal center-derived antibodies promote atherosclerosis plaque size and stability","volume":"139","author":"Centa","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0095","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0100","article-title":"The PCSK9 revolution: Current status, controversies, and future directions","author":"Warden","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0105","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.12.039_b0110","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCULATIONAHA.110.006411","article-title":"Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia","volume":"124","author":"Maganto-Garcia","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0120","doi-asserted-by":"crossref","first-page":"107-17","DOI":"10.1093\/cvr\/cvu002","article-title":"Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice","volume":"102","author":"Kita","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0125","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.112.099044","article-title":"Cytokine therapy with interleukin-2\/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis","volume":"126","author":"Dinh","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0135","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0140","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/CIRCRESAHA.116.309764","article-title":"Atherosclerosis-driven treg plasticity results in formation of a dysfunctional subset of plastic IFNgamma+ Th1\/Tregs","volume":"119","author":"Butcher","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.ATV.14.1.32","article-title":"Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL","volume":"14","author":"Yla-Herttuala","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.vaccine.2019.12.039_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.ATV.21.1.95","article-title":"Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice","volume":"21","author":"Tsimikas","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0021-9150(98)00015-X","article-title":"Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis","volume":"138","author":"George","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-511X-6-32","article-title":"Effect of immunization against ox-LDL with two different antigens on formation and development of atherosclerosis","volume":"6","author":"Asgary","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0165","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1194\/jlr.M053256","article-title":"Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine","volume":"55","author":"Gonen","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cei.12651","article-title":"Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus","volume":"181","author":"Svenungsson","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0175","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.atherosclerosis.2013.11.041","article-title":"Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis","volume":"232","author":"McLeod","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0180","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/j.atherosclerosis.2006.12.014","article-title":"Autoantibody against the amino acid sequence 661\u2013680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events","volume":"194","author":"Fredrikson","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/ATVBAHA.115.306938","article-title":"Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events","volume":"36","author":"Bjorkbacka","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0190","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/01.ATV.0000067935.02679.B0","article-title":"Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease","volume":"23","author":"Fredrikson","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0195","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08916930500050525","article-title":"Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression","volume":"38","author":"Fredrikson","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.vaccine.2019.12.039_b0200","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.bbrc.2005.10.141","article-title":"Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-\/-) mice","volume":"338","author":"Chyu","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2019.12.039_b0205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2796.2008.01995.x","article-title":"Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies","volume":"264","author":"Fredrikson","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2019.02.001","article-title":"Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system","volume":"283","author":"Momtazi-Borojeni","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0215","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vaccine.2019.12.039_b0220","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.039_b0225","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fimmu.2013.00493","article-title":"Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100","volume":"4","author":"Tse","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0230","doi-asserted-by":"crossref","first-page":"H781","DOI":"10.1152\/ajpheart.00798.2016","article-title":"Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells","volume":"312","author":"Kimura","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0235","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.117.031420","article-title":"Regulatory CD4(+) T cells recognize MHC-II-restricted peptide epitopes of apolipoprotein B","author":"Kimura","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0240","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20110308","article-title":"T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse","volume":"208","author":"Moran","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1379\/CSC-155R.1","article-title":"Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe?","volume":"11","author":"Wu","year":"2006","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.vaccine.2019.12.039_b0250","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/ATVBAHA.110.217877","article-title":"Heat shock protein 60 and immune inflammatory responses in atherosclerosis","volume":"31","author":"Grundtman","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0255","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.vaccine.2011.03.105","article-title":"Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"29","author":"Jing","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.039_b0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.atherosclerosis.2015.06.044","article-title":"Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: Preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides","volume":"242","author":"Grundtman","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0265","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/ATVBAHA.107.151274","article-title":"Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis","volume":"27","author":"van Puijvelde","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.imbio.2011.06.006","article-title":"Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(-)\/(-) mice","volume":"217","author":"Klingenberg","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2019.12.039_b0275","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00011-013-0599-y","article-title":"Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies","volume":"62","author":"Mundkur","year":"2013","journal-title":"Inflamm Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fphar.2018.00055","article-title":"Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: how human genetics can help to this issue. A narrative review","volume":"9","author":"Fava","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrg.2016.160","article-title":"Genetics of coronary artery disease: discovery, biology and clinical translation","volume":"18","author":"Khera","year":"2017","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.vaccine.2019.12.039_b0290","first-page":"1241","article-title":"A decade of genome-wide association studies for coronary artery disease: the challenges ahead","volume":"114","author":"Erdmann","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0295","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1161\/ATVBAHA.112.300112","article-title":"A systems biology framework identifies molecular underpinnings of coronary heart disease","volume":"33","author":"Huan","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0300","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1161\/01.CIR.0000092891.55157.A7","article-title":"Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis","volume":"108","author":"Karvonen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0305","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.ATV.0000166518.96137.38","article-title":"Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques","volume":"25","author":"Goncalves","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0310","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ebiom.2016.06.012","article-title":"High serum immunoglobulin G and M levels predict freedom from adverse cardiovascular events in hypertension: a nested case-control substudy of the anglo-scandinavian cardiac outcomes trial","volume":"9","author":"Khamis","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.12.039_b0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0140-6736(93)92613-X","article-title":"Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis","volume":"341","author":"Xu","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.039_b0320","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.carpath.2014.03.001","article-title":"Adventitial macrophage and lymphocyte accumulation accompanying early stages of human coronary atherogenesis","volume":"23","author":"Kortelainen","year":"2014","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0325","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/CIRCULATIONAHA.105.537712","article-title":"Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism","volume":"113","author":"De Palma","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2019.12.039_b0330","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaut.2012.07.006","article-title":"Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions","volume":"39","author":"Almanzar","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2019.12.039_b0335","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2007.03.546","article-title":"The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes","volume":"124","author":"Han","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0340","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.atherosclerosis.2011.03.043","article-title":"Activation of Th17\/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome","volume":"217","author":"Zhao","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2008.01.009","article-title":"The Th17\/Treg imbalance in patients with acute coronary syndrome","volume":"127","author":"Cheng","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0350","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/364710","article-title":"Decreased regulatory T cells in vulnerable atherosclerotic lesions: imbalance between pro- and anti-inflammatory cells in atherosclerosis","volume":"2015","author":"Rohm","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.vaccine.2019.12.039_b0355","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/eurheartj\/ehl222","article-title":"Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes","volume":"27","author":"Mor","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vaccine.2019.12.039_b0360","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.4049\/jimmunol.0901076","article-title":"Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques","volume":"183","author":"Burioni","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0365","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.4049\/jimmunol.1202870","article-title":"Characterization of resident B cells of vascular walls in human atherosclerotic patients","volume":"191","author":"Hamze","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2016.00387","article-title":"Artery tertiary lymphoid organs: powerhouses of atherosclerosis immunity","volume":"7","author":"Yin","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0375","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/ATVBAHA.115.306983","article-title":"Artery tertiary lymphoid organs control multilayered territorialized atherosclerosis B-Cell responses in aged ApoE-\/- mice","volume":"36","author":"Srikakulapu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0380","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm876","article-title":"Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL","volume":"9","author":"Binder","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/ATVBAHA.113.302667","article-title":"Circulating CD40+ and CD86+ B cell subsets demonstrate opposing associations with risk of stroke","volume":"34","author":"Mantani","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0390","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","article-title":"IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis","volume":"193","author":"Erbel","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0395","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0400","first-page":"864","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.12.039_b0405","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022452","article-title":"Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I\/II clinical trial","volume":"8","author":"Zhao","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.12.039_b0410","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2015.14094","article-title":"PCSK9 inhibitors","volume":"145","author":"Gencer","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.vaccine.2019.12.039_b0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(03)00137-0","article-title":"The safety and immunogenicity of a CETP vaccine in healthy adults","volume":"169","author":"Davidson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0420","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000247","article-title":"Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis","volume":"2","author":"Ren","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.vaccine.2019.12.039_b0425","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ahj.2016.04.003","article-title":"Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE)","volume":"177","author":"Ren","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.vaccine.2019.12.039_b0430","first-page":"55","article-title":"Adipose tissue inflammation in obesity and metabolic syndrome","volume":"8","author":"Nishimura","year":"2009","journal-title":"Discov Med"},{"key":"10.1016\/j.vaccine.2019.12.039_b0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-511X-9-14","article-title":"Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study","volume":"9","author":"Bourinbaiar","year":"2010","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.vaccine.2019.12.039_b0440","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/j.vaccine.2010.01.032","article-title":"Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices","volume":"28","author":"Bourinbaiar","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.039_b0445","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2019.12.039_b0450","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/14712598.6.12.1311","article-title":"Ii-Key\/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines","volume":"6","author":"Kallinteris","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.12.039_b0455","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.vaccine.2012.02.031","article-title":"CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key\/MHC class II epitope hybrid vaccines","volume":"30","author":"Xu","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.039_b0460","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2017.6.1.15","article-title":"The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants","volume":"6","author":"Kim","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0465","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.mib.2013.06.002","article-title":"Engineering lactococci and lactobacilli for human health","volume":"16","author":"Bermudez-Humaran","year":"2013","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0470","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1586\/14760584.2014.953064","article-title":"Transgenic plants: a 5-year update on oral antipathogen vaccine development","volume":"13","author":"Hernandez","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.039_b0475","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s12033-014-9793-6","article-title":"Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine","volume":"56","author":"Salazar-Gonzalez","year":"2014","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0480","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/ATVBAHA.109.202671","article-title":"Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis","volume":"30","author":"Klingenberg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nbt0212-124c","article-title":"Toll-like receptor blocker slows beta cell death in type 1 diabetes","volume":"30","author":"Aldridge","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2019.12.039_b0490","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/dmrr.712","article-title":"Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial","volume":"23","author":"Raz","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.vaccine.2019.12.039_b0495","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCRESAHA.116.308648","article-title":"CCR5+T-bet+FoxP3+ effector CD4 T cells drive atherosclerosis","volume":"118","author":"Li","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.vaccine.2019.12.039_b0500","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:07Z","timestamp":1759401847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":100,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X19316810"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for an atherosclerosis vaccine: From mice to humans","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}